吉西他滨联合铂类化疗药物治疗晚期非小细胞肺癌临床观察

The Clinical Observation of the Treatment of Advanced Non-Small Cell Lung Cancer with Gemcitabine plus Platinum Complexes

目的评价吉西他滨联合铂类化疗药物治疗晚期非小细胞肺癌（NSCLC）的临床疗效与毒副反应。方法51例晚期NSCLC患者接受吉西他滨与铂类联合化疗：吉西他滨1000mg／m^2，第1天和第8天；顺铂25mg／m^2，第1-3天或卡铂AUC=5第1天；21天为1个周期。结果完全缓解3例，部分缓解20例，有效率45．1％。中位疾病进展时间5．2个月，中位生存期10．1个月，1年生存率39．2％。主要毒副反应为血液学毒性，恶心呕吐等。结论吉西他滨联合铂类化疗药物是治疗晚期NSCLC安全、有效的联合化疗方案，值得临床进一步研究。

Objective To evaluate the efficacy and toxicity of combination chemotherapy with gemcitabine plus cisplatin or carboplatin for the patients With advanced non-small cell lung cancer（ NSCLC）.Methods Fifty-one patients with advanced NSCLC were treated by gemcitabine 1000 mg/m^2 on d1.8 and cisplatifi 25mg/m^2 on d1～3 or carboplatin AUG = 5 on d1, every 21 days as one cycle. Results 3 cases showed complete response and 20 cases partial response with an overall response rate of 45.1%. Median time to progression was 5.2 months, and 1-year survival rate was 39.2 % with a median survival time of 10.1 months. Toxicity mainly included myelosuppression, nausea/vomiting. Conclusions Gemcitabine plus cisplatin or carboplatin chemotherapy is safe and effective for patients With advanced NSCLC.